You don't know what you're talking about. This stock has a nice upward spike every year and a violent one every couple of years. Both are overdue. In the first quarter of 2012 there was a nice spike ($.30 to $.60) when Teva and OEP saw positive early results. As enrollment accelerates and investigators, health care workers, patients, and patients' families see positive results 3 weeks after treatment word will get out.